196 related articles for article (PubMed ID: 28514206)
1. First-in-Human PET/CT Imaging of Metastatic Neuroendocrine Neoplasms with Cyclotron-Produced
Singh A; van der Meulen NP; Müller C; Klette I; Kulkarni HR; Türler A; Schibli R; Baum RP
Cancer Biother Radiopharm; 2017 May; 32(4):124-132. PubMed ID: 28514206
[No Abstract] [Full Text] [Related]
2. Clinical evaluation of the radiolanthanide terbium-152: first-in-human PET/CT with
Baum RP; Singh A; Benešová M; Vermeulen C; Gnesin S; Köster U; Johnston K; Müller D; Senftleben S; Kulkarni HR; Türler A; Schibli R; Prior JO; van der Meulen NP; Müller C
Dalton Trans; 2017 Oct; 46(42):14638-14646. PubMed ID: 28825750
[TBL] [Abstract][Full Text] [Related]
3. Intraoperative somatostatin receptor detection after peptide receptor radionuclide therapy with (177)Lu- and (90)Y-DOTATOC (tandem PRRNT) in a patient with a metastatic neuroendocrine tumor.
Todorović-Tirnanić M; Kaemmerer D; Prasad V; Hommann M; Baum RP
Recent Results Cancer Res; 2013; 194():487-96. PubMed ID: 22918778
[TBL] [Abstract][Full Text] [Related]
4. The impact of 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors.
Frilling A; Sotiropoulos GC; Radtke A; Malago M; Bockisch A; Kuehl H; Li J; Broelsch CE
Ann Surg; 2010 Nov; 252(5):850-6. PubMed ID: 21037441
[TBL] [Abstract][Full Text] [Related]
5. Promises of cyclotron-produced 44Sc as a diagnostic match for trivalent β--emitters: in vitro and in vivo study of a 44Sc-DOTA-folate conjugate.
Müller C; Bunka M; Reber J; Fischer C; Zhernosekov K; Türler A; Schibli R
J Nucl Med; 2013 Dec; 54(12):2168-74. PubMed ID: 24198390
[TBL] [Abstract][Full Text] [Related]
6. Head-to-Head Comparison of
Johnbeck CB; Knigge U; Loft A; Berthelsen AK; Mortensen J; Oturai P; Langer SW; Elema DR; Kjaer A
J Nucl Med; 2017 Mar; 58(3):451-457. PubMed ID: 27660147
[TBL] [Abstract][Full Text] [Related]
7. Additional information gained by positron emission tomography with (68)Ga-DOTATOC for suspected unknown primary or recurrent neuroendocrine tumors.
Nakamoto Y; Sano K; Ishimori T; Ueda M; Temma T; Saji H; Togashi K
Ann Nucl Med; 2015 Jul; 29(6):512-8. PubMed ID: 25894056
[TBL] [Abstract][Full Text] [Related]
8. Scandium and terbium radionuclides for radiotheranostics: current state of development towards clinical application.
Müller C; Domnanich KA; Umbricht CA; van der Meulen NP
Br J Radiol; 2018 Nov; 91(1091):20180074. PubMed ID: 29658792
[TBL] [Abstract][Full Text] [Related]
9. Localization of Unknown Primary Site with
Menda Y; O'Dorisio TM; Howe JR; Schultz M; Dillon JS; Dick D; Watkins GL; Ginader T; Bushnell DL; Sunderland JJ; Zamba GKD; Graham M; O'Dorisio MS
J Nucl Med; 2017 Jul; 58(7):1054-1057. PubMed ID: 28153957
[TBL] [Abstract][Full Text] [Related]
10. Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
Recent Results Cancer Res; 2013; 194():353-71. PubMed ID: 22918768
[TBL] [Abstract][Full Text] [Related]
11. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
[TBL] [Abstract][Full Text] [Related]
12. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of dual-phase scanning using (68)Ga-DOTATOC-PET/CT in the detection of neuroendocrine tumours.
Nakamoto Y; Ishimori T; Sano K; Temma T; Ueda M; Saji H; Togashi K
Clin Radiol; 2016 Oct; 71(10):1069.e1-1069.e5. PubMed ID: 27210241
[TBL] [Abstract][Full Text] [Related]
14. Potential role of (68)Ga-DOTATOC PET/CT in screening for pancreatic neuroendocrine tumour in patients with von Hippel-Lindau disease.
Prasad V; Tiling N; Denecke T; Brenner W; Plöckinger U
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):2014-20. PubMed ID: 27293206
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of feasibility and image quality of 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors.
Gaertner FC; Beer AJ; Souvatzoglou M; Eiber M; Fürst S; Ziegler SI; Brohl F; Schwaiger M; Scheidhauer K
Invest Radiol; 2013 May; 48(5):263-72. PubMed ID: 23385399
[TBL] [Abstract][Full Text] [Related]
16. Limited Value of Ga-68-DOTATOC-PET-CT in Routine Screening of Patients with Multiple Endocrine Neoplasia Type 1.
Albers MB; Librizzi D; Lopez CL; Manoharan J; Apitzsch JC; Slater EP; Bollmann C; Kann PH; Bartsch DK
World J Surg; 2017 Jun; 41(6):1521-1527. PubMed ID: 28138732
[TBL] [Abstract][Full Text] [Related]
17. Developments toward the Implementation of
van der Meulen NP; Hasler R; Talip Z; Grundler PV; Favaretto C; Umbricht CA; Müller C; Dellepiane G; Carzaniga TS; Braccini S
Molecules; 2020 Oct; 25(20):. PubMed ID: 33066650
[No Abstract] [Full Text] [Related]
18. Bone metastases in patients with neuroendocrine tumor: 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy.
Putzer D; Gabriel M; Henninger B; Kendler D; Uprimny C; Dobrozemsky G; Decristoforo C; Bale RJ; Jaschke W; Virgolini IJ
J Nucl Med; 2009 Aug; 50(8):1214-21. PubMed ID: 19617343
[TBL] [Abstract][Full Text] [Related]
19. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
[TBL] [Abstract][Full Text] [Related]
20. ²¹³Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience.
Kratochwil C; Giesel FL; Bruchertseifer F; Mier W; Apostolidis C; Boll R; Murphy K; Haberkorn U; Morgenstern A
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2106-19. PubMed ID: 25070685
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
